-
Human Metapneumovirus (hMPV): Systematic Literature Review of Economic and Humanistic Disease Burden in Adults
Sep 9, 2025, 16:22 PM -
Costing Analysis for the Management of Localized Renal Cell Carcinoma From the UK NHS Perspective
Sep 9, 2025, 16:22 PM -
Variations in Screening and Medication Takeup Rates for Alzheimer’s Disease
Sep 9, 2025, 16:22 PM -
Inter-Version Comparison of the Boston Carpal Tunnel Questionnaire: A Clinical Validation Study of the Decision Tree-Based Version
Sep 9, 2025, 16:22 PM -
Surviving but Not Earning? Long-term Income Trajectories in Working-Age mIDH Glioma Patients: Stratification by Radiotherapy/Chemotherapy Exposure
Sep 9, 2025, 16:22 PM -
Challenges in PICO Definition for HTDs: Lessons From Durvalumab Exercise
Sep 9, 2025, 16:22 PM -
Improving Kidney Exchange Program Effectiveness and Equity by Using Allele and Eplet HLA Compatibility Technologies
Sep 9, 2025, 16:22 PM -
Structural Uncertainty (SU) in Model-Based Economics Appraisal (MBEA): A Document Review of the French National Authority for Health (HAS)
Sep 9, 2025, 16:22 PM -
Can Generative Artificial Intelligence (GenAI) Be Leveraged to Automate Scoping Searches of Systematic Literature Reviews (SLRs)?
Sep 9, 2025, 16:22 PM -
AI for Precision Oncology Evidence: Case Study Research From British Columbia, Canada
Sep 9, 2025, 16:22 PM -
Trends and Tensions in NICE Severity Modifiers: Analyzing the Acceptance and Critique of Manufacturer Severity Modifier Proposals in Recent Appraisals
Sep 9, 2025, 16:22 PM -
Estimating the Cost-Effectiveness of Tumor-Treating Fields With Gemcitabine and Nabpaclitaxel for Frontline Treatment of Locally Advanced Pancreatic Adenocarcinoma
Sep 9, 2025, 16:22 PM -
Natural Language Processing Solution (REALLI) to Evaluate the Limitations of the French National Health Insurance Database (SNDS): Example of HER2+ Metastatic Breast Cancer
Sep 9, 2025, 16:22 PM -
The Health Impact of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab Treatment for High-Risk Early Stage Triple-Negative Breast Cancer (eTNBC) in Türkiye
Sep 9, 2025, 16:22 PM -
Budget Impact of Anakinra in Turkiye: An Analysis From the Social Security Institution’s Perspective
Sep 9, 2025, 16:22 PM -
Early Economic Modeling of Mutant TNF (mutTNF) As a BBB-Permeabilizing Adjunct in Breast Cancer Brain Metastases: A UK NHS Perspective
Sep 9, 2025, 16:22 PM -
Out-of-Pocket Expenditures of Families Affected by Epidermolysis Bullosa in Europe
Sep 9, 2025, 16:22 PM -
Are We There Yet? Mapping Member State Readiness for Local Implementation of the EU Health Technology Assessment (HTA) Regulation
Sep 9, 2025, 16:22 PM -
Deep Brain Stimulation: A Cost-Saving Treatment Option for Extreme Treatment-Refractory Obsessive-Compulsive Disorder in the UK?
Sep 9, 2025, 16:22 PM -
Bridging the Gap: What Spain Can Learn From European Leaders in Digital Therapy Reimbursement
Sep 9, 2025, 16:22 PM
